Creative Medical reports 65% reduction in average pain scores in Ultrasome knee osteoarthritis pilot study
CELZ•Creative Medical Technology Holdings reported a 93% response rate in a 30-patient knee osteoarthritis pilot of its investigational Ultrasome therapy. Over six months, average pain scores fell approximately 65%, WOMAC scores declined 52%, and no serious adverse events were reported.
1. Pilot study results
Creative Medical Technology Holdings reported results from a 30-patient, open-label, single-arm pilot study of investigational cell-free therapy Ultrasome for knee osteoarthritis. The company reported a 93% response rate; average pain scores fell approximately 65% and WOMAC symptom scores declined 52% over six months. Average knee-related quality-of-life scores rose approximately 35 points, and no serious adverse events were reported during follow-up. The study had no randomized or sham-controlled comparator.
2. Laboratory findings
Laboratory studies showed significant reductions in markers associated with cartilage degradation and inflammatory signaling, supporting further platform development.
